Spondylolisthesis Market

Market Overview:

The 7 major spondylolisthesis markets reached a value of US$ 17.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 29.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.79% during 2024-2034.

The spondylolisthesis market has been comprehensively analyzed in IMARC's new report titled "Spondylolisthesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spondylolisthesis refers to a medical disorder in which one of the vertebrae in the spinal column slides out of its proper position onto the vertebra below it. This can occur in any part of the spine, but generally, it takes place in the lower back (lumbar spine). The prominent symptoms of the ailment include severe back pain or nerve congestion, resulting in leg discomfort or numbness. Individuals suffering from spondylolisthesis may also experience muscle spasms in the hamstring (back thigh muscles), difficulty walking or standing for long periods, back stiffness, pain while bending over, weakness or tingling in the foot, etc. In severe cases, this condition may impair a person's quality of life by limiting mobility and impacting emotional well-being. The diagnosis of the illness is mainly made by reviewing the reported clinical features, medical history, and a physical test. A healthcare provider may also perform numerous other examinations, such as spinal X-rays, magnetic resonance imaging, computed tomography, etc., to look for misplaced bones or rule out further possible soft tissue diseases.

The rising cases of bone fractures or cracks which weaken the vertebrae, thereby enhancing their likelihood of slipping forward, backward, or over a bone below, are primarily driving the spondylolisthesis market. In addition to this, the expanding geriatric population, who are more prone to degenerative spine conditions due to wear and tear on the spine, is also bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, such as ibuprofen and naproxen, which target the intervertebral joints and the nerve root to reduce pain, is acting as another significant growth-inducing factor. In line with this, the inflating application of epidural steroid injections that can be injected directly into the affected area to diminish swelling and control pressure on the larger nerves quickly is further propelling the market growth. Additionally, the emerging popularity of non-fusion spinal decompression surgery for treating the ailment since it aids in preserving the motion of the spine, lowering the risk of adjacent segment disease, and relieving neurological symptoms, is expected to drive the spondylolisthesis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the spondylolisthesis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for spondylolisthesis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spondylolisthesis market in any manner.

Key Highlights:

• Degenerative spondylolisthesis primarily affects adults and is more common in females than males, with an elevated risk in the obese.
• Black women are approximately three times more likely to be affected than white women.
• Elderly Caucasian Americans have a greater incidence of degenerative spondylolisthesis than older Chinese.
• Grade I spondylolisthesis accounts for 75% of all occurrences.
• Spondylolisthesis is most prevalent at the L5-S1 level, with the L5 vertebral body translating anteriorly onto the S1 vertebral body.

Drugs:

NVD-001, Novadip's first autologous product, is a clinical-stage cell-based therapy that represents a new paradigm in regenerative medicine. NVD-001 is an autologous cellular medicinal product derived from adipose tissue culture, which results in osteogenic cells after ex vivo isolation, expansion, and differentiation of pluripotent adipose-tissue stem cells (ASC) and combination with an allogeneic fully demineralized bone matrix to form a 3D bone implant.

AK-1320 MS is a drug developed by Asahi Kasei Pharma Corp. to treat degenerative spondylolisthesis and spinal stenosis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the spondylolisthesis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the spondylolisthesis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current spondylolisthesis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the spondylolisthesis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the spondylolisthesis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the spondylolisthesis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of spondylolisthesis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of spondylolisthesis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of spondylolisthesis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with spondylolisthesis across the seven major markets?
• What is the size of the spondylolisthesis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of spondylolisthesis?
• What will be the growth rate of patients across the seven major markets?
   

Spondylolisthesis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for spondylolisthesis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spondylolisthesis market?
• What are the key regulatory events related to the spondylolisthesis market?
• What is the structure of clinical trial landscape by status related to the spondylolisthesis market?
• What is the structure of clinical trial landscape by phase related to the spondylolisthesis market?
• What is the structure of clinical trial landscape by route of administration related to the spondylolisthesis market?